Bystander effect produced by radiolabeled tumor cells *in vivo*

Lanny Y. Xue*, Nicholas J. Butler*, G. Mike Makrigiorgos†, S. James Adelstein*, and Amin I. Kassis*‡

Departments of *Radiology and †Radiation Oncology, Harvard Medical School, Boston, MA 02115

The bystander effect, originating from cells irradiated *in vitro*, describes the biologic response(s) of surrounding cells not directly targeted by a radiation insult. To overcome the limitations of *in vitro* tissue culture models and determine whether a bystander effect that is initiated by the *in vivo* decay of a radionuclide can be demonstrated in an animal, the ability of 5-[^{125}I]iodo-2′-deoxyuridine (^{125}IUdR)-labeled tumor cells to exert a damaging effect on neighboring unlabeled tumor cells growing s.c. in nude mice has been investigated. When mice are injected with a mixture of human colon LS174T adenocarcinoma cells and LS174T cells prelabeled with lethal doses of DNA-incorporated ^{125}I, a distinct inhibitory effect on the growth of s.c. tumor (derived from unlabeled cells) is observed. Because (*i*) the ^{125}I present within the cells is DNA-bound, (*ii*) ≈99% of the electrons emitted by the decaying ^{125}I atoms have a subcellular range (<0.5 μm), and (*iii*) the overall radiation dose deposited by radiolabeled cells in the unlabeled cells within the growing tumor is <10 cGy, we conclude that the results obtained are a consequence of a bystander effect that is generated *in vivo* by factor(s) present within and/or released from the ^{125}IUdR-labeled cells. These *in vivo* findings significantly impact the current dogma for assessing the therapeutic potential of internally administered radionuclides. They also call for reevaluation of the approaches currently used for estimating the risks to individuals and populations inadvertently exposed internally to radioactivity as well as to patients undergoing routine diagnostic nuclear medical procedures.

Studies in recent years have demonstrated that a radiobiologic phenomenon termed the "bystander effect" can be observed in mammalian cells grown *in vitro*. Bystander damage describes biologic effects, originating from irradiated cells, that occur in unirradiated neighboring cells. Several investigators have reported that when α-particles traverse a small fraction of a cell population *in vitro*, lower rates of survival and higher rates of genetic change are observed than those predicted from direct-ionization-only models (1–6). These changes include increased levels of sister chromatid exchanges, mutations, and micronuclei formation, changes in gene expression, and oncogenic transformation. Cell survival is likewise compromised when cells are cocultured with tritiated thymidine-labeled cells (7, 8) and iodine-125 (9). Similarly, the bystander effect has been reported for microcolonies that have been γ irradiated (10) and for cells exposed to media from γ-irradiated cells (10, 11). Evidence from these reports challenges the past half-century's tenet that radiation produces effects only in cells whose DNA has been damaged either through direct ionization or indirectly (for example, through hydroxyl radicals produced in water molecules in the immediate vicinity of the DNA).

Whether radiation-induced bystander effects represent a phenomenon that occurs only *ex vivo*, i.e., are a byproduct of *in vitro* conditions and manipulations, or whether they are factual *in vivo* events has not been fully examined. Consequently, the extension of conclusions derived from *in vitro* studies to the *in vivo* situation is uncertain. The demonstration of a bystander effect with an *in vivo* system and the elucidation of the underlying mechanisms of an *in vivo* bystander effect would go a long way in translating its implications for humans.

Recently, Watson *et al.* (12) demonstrated chromosomal instability in the progeny of unirradiated bone marrow cells mixed with cells exposed *ex vivo* to neutrons and transplanted into recipient mice. In this novel system, a sex-mismatch transplantation protocol provides a three-way marker system and allows the investigators to distinguish not only host-derived cells from donor-derived cells, but also irradiated donor stem-cell-derived cells from nonirradiated donor stem-cell-derived cells. These studies thus provide the first demonstration of an *in vivo* bystander mechanism, albeit with cells that were irradiated *ex vivo* before their administration.

To determine whether a bystander effect can be demonstrated with mammalian cells irradiated *in vivo*, we have investigated the ability of tumor cells, prelabeled with lethal radioactive concentrations of 5-[^{125}I]iodo-2′-deoxyuridine (^{125}IUdR) and, thus, destined to die, to exert a radiobiologic effect on surrounding unlabeled tumor cells growing s.c. in nude mice. To this end, human colon adenocarcinoma LS174T cells, preincubated with the thymidine analog ^{125}IUdR, were coinjected, s.c. with unlabeled cells into nude mice, and tumor growth was measured at various times to determine the tumor responsiveness to the coinjected "dying" ^{125}IUdR-labeled cells. Under these experimental conditions (*i*) the vast majority of the radiation dose is accumulated in the radiolabeled cells after s.c. injection, (*ii*) ≈99% of the electrons emitted by the decaying atoms of the Auger electron emitter ^{125}I have a subcellular range (<0.5 μm) (13–15) and are, therefore, confined principally to the radiolabeled cells (15, 16), and (*iii*) the overall radiation dose deposited by radiolabeled cells in the unlabeled cells within the growing tumors is <10 cGy. Consequently, any retardation/inhibition of tumor growth would be a consequence of an *in vivo* induced bystander effect, presumably initiated by the irradiation of the labeled cell DNA by Auger electrons.

Materials and Methods

Mice. Male NCr nude mice, the standard athymic model for the National Cancer Institute, were obtained at 4–5 weeks of age from Taconic Farms. The mice were housed in a Harvard University animal facility and fed ad libitum. We used the mice for experiments when they were 6–8 weeks old.

Tissue Culture. LS174T cells, an adenocarcinoma developed from human colon cancer, were procured from American Type Culture Collection. The cells were grown at 37°C with 5% CO_2 in Dulbecco's Modified Essential Medium, supplemented with sodium pyruvate, nonessential amino acids (Invitrogen), and 10% FBS (HyClone).

For all experiments, we trypsinized logarithmically growing LS174T cells, determined their number per milliliter with a hemocytometer, and assessed their viability with trypan blue. The cells were suspended in complete medium at a concentration of 2×10^7 cells/ml before being mixed with other cell preparations. All

MEDICAL SCIENCES

injectates contained a total of 2×10^6 tumor cells (dead, ^{125}IUdR-labeled, unlabeled, and/or externally irradiated).

Dead Cell Preparations. Dead LS174T tumor cells, used as "spacers," ensured a consistent spatial arrangement of viable cells in all groups. These cells, harvested from growing healthy monolayers and suspended in complete medium (2×10^7 cells/ml), underwent three successive freeze–thaw cycles, from $-135°C$ (Queue Cryostar $-135°C$ freezer) to $37°C$ (water bath). Trypan-blue staining confirmed that 100% of the cells were no longer viable.

^{125}IUdR-Labeled Cell Preparations. Logarithmically growing LS174T tumor cells were incubated with 3–3.5 μCi/ml ^{125}IUdR (ICN; 1 Ci = 37 GBq) for 48 h at $37°C$ with 5% CO_2. They were then washed three times with PBS to remove non-DNA-associated ^{125}IUdR. The labeled cells were trypsinized and passed repeatedly through a 20-gauge needle to produce a single-cell suspension, thus ensuring that each injection bolus contained the same cell count. The trypan-blue dye-exclusion test indicated that >90% of the labeled cell population were viable in all experiments. Trichloroacetic acid precipitation confirmed that all remaining cell-associated radioactivity was covalently bound to DNA. The radioactivity per cell was assessed with a Wallac 1480 γ counter and was found to range from 0.15 pCi per cell to 0.25 pCi per cell (with a targeted value of 0.20 pCi per cell). Autoradiography illustrated that the labeling index in all experiments was, on average, $\approx$80%. The radioiodinated cells were resuspended in complete medium at a concentration of 2×10^7 cells/ml before use. When required, dead ^{125}IUdR-labeled cells were prepared by freezing and thawing (three cycles) a portion of the labeled cells.

Externally Irradiated Cell Preparations. Logarithmically growing LS174T cells were trypsinized and suspended in complete medium (2×10^7 cells/ml). The cells were irradiated with a Gammacell 220 cobalt irradiator (15 cGy/sec). The radiation doses varied from 50 cGy to 2,000 cGy, depending on the experimental requirements. The irradiated cells were immediately mixed with an equal number of live cells and injected into mice.

Tumor Cell Administration. Cells in 0.1 ml of medium were administered by s.c. injection in the anterior right flank of nude mice. Any visible leakage from the injection site resulted in elimination of the animal from the study. Each study group consisted of 10 animals. For ^{125}I-cell retention studies, cells were introduced s.c. into both hind legs of each mouse.

Autoradiography. A small fraction (1×10^6 to 2×10^6) of the prepared ^{125}IUdR-labeled cells were seeded into Lab-Tek II chamber slides (Nalge Nunc) and returned to the incubator for 2–3 h. This time frame allowed for cell adhesion, but was not sufficiently long for cell division. After the cells attached, the medium was decanted and the cells were fixed with 70% ethyl alcohol for 3 min. Distilled water provided a final rinse.

In a darkroom, the slides were dipped once or twice in a mixture of NTB2 emulsion (Eastman Kodak) and distilled water (1:1) at $42°C$, the emulsion was allowed to dry for 10 min, and the slides were stored in a dark box with Drierite (anhydrous $CaSO_4$) at $4°C$ for 3–5 days. Finally, the slides were dipped for 5 min in Kodak Developer D-19, washed in distilled water, immersed in Rapid Fixer for 5 min, and washed again in distilled water. The cells were assessed under a light microscope for the presence of nuclear grains.

^{125}I-Cell Retention Studies. To obtain ^{125}IUdR-labeled-cell radioactivity-retention data, mice previously injected with a mixture of 5×10^5 ^{125}IUdR-labeled cells and an equal number of unlabeled tumor cells were killed at various time points (3 h to 2 weeks). Their tumor-bearing hind legs were removed and counted in a γ counter.

Tumor Measurement. One week after tumor-cell implantation in mice, tumor growth was examined. Volume assessment commenced once the tumors reached a palpable size. Tumors were measured in three dimensions, length (L), width (W), and height (H), by using calipers. After subtracting skin thickness from each, tumor volumes were calculated with the formula $V = (L \times W \times H)/2$.

Cell Sizing. Tumor, from an injectate containing 1×10^6 ^{125}IUdR-labeled cells and 1×10^6 live LS174T cells, was removed from nude mice 14 days after inoculation. The tissue was fixed with formalin, sectioned (5-μm thick), and stained with hematoxylin/eosin. Cell diameters were measured under a microscope.

Results

Distinct Patterns of *in Vivo* Bystander Effect. To characterize the *in vivo* bystander effect of the dying ^{125}IUdR-labeled cells on neighboring or distant cells, the effect of varying numbers of ^{125}IUdR-labeled cells on tumor growth in nude mice was assessed (Fig. 1). There was no detectable tumor growth when 1×10^6 ^{125}IUdR-labeled cells (0.19 pCi per cell) were exclusively inoculated into nude mice. However, when ^{125}IUdR-labeled cells were coadministered with live LS174T cells, distinct patterns of *in vivo* tumor growth inhibition/retardation were observed. For example, when 1×10^6 ^{125}IUdR-labeled cells and 1×10^6 unlabeled cells were injected, the rate of tumor growth was substantially and significantly ($P < 0.01$) lower than that in the control animals (1×10^6 unlabeled tumor cells + 1×10^6 dead unlabeled cells). Dosimetric estimates indicate that under these experimental conditions, the total dose deposited in these s.c. tumors was 6.9 cGy (see *Supporting Text*, which is published as supporting information on the PNAS web site, www.pnas.org, for dose calculations). Tumor growth retardation was also significant when 2×10^5 radiolabeled cells and 1×10^6 unlabeled cells were injected; in this case the ratio of labeled-to-unlabeled cells is lower (1:5) and the cumulative dose in the unlabeled tumor cells is 2.3 cGy only. Because such a reduction in the ratio (*i*) increases the distances between the radiolabeled cells, (*ii*) decreases the number of radiolabeled cells in contact with unlabeled cells, and (*iii*) leads to a corresponding decrease in the total radiation dose deposited in these s.c. tumors (from $\approx$7 to $\approx$2 cGy), we conclude that the presence of the dying ^{125}IUdR-labeled cells among the growing tumor cells resulted in a distinct bystander effect. A somewhat lesser decrease in the growth of tumors was observed when the ratio of ^{125}IUdR-labeled cells to the surrounding unlabeled cells was only 1:10 (Fig. 1); under these experimental conditions, the differences in the growth of these tumors were not significantly different from the controls ($P > 0.05$), though the trend is clear.

In another set of experiments, the radioactivity present within the growing tumors was determined after the coinjection of 1×10^6 ^{125}IUdR-labeled cells and 1×10^6 unlabeled cells or the coadministration of 2×10^5 ^{125}IUdR-labeled cells, 1×10^6 unlabeled cells, and 8×10^5 dead unlabeled cells. No differences were observed between the tumor volumes for the two groups of animals 15 days after tumor inoculation (respectively 61% and 62% of the volumes found in the control animals) (Fig. 2). However, there was a substantial difference at that time in the amount of radioactivity still present within the tumor masses of the two groups, further demonstrating the absence of any correlation between the radiation dose and the bystander effect.

Reutilization of Released ^{125}IUdR by Tumor Cells. Mammalian cells are efficiently killed after the decay of DNA-incorporated ^{125}I (15, 17–19). In such studies, very low doses of ^{125}I ($\approx$0.05 pCi per

Fig. 1. Patterns of *in vivo*, [125]IUdR-labeled, LS174T-cell-induced bystander effect. Five groups of nude mice were injected s.c. with 1 × 10⁶ live unlabeled cells and 1 × 10⁶ dead unlabeled cells (●); 1 × 10⁵ [125]IUdR-labeled cells, 1 × 10⁶ live unlabeled cells, and 9 × 10⁵ dead unlabeled cells (○); 2 × 10⁵ [125]IUdR-labeled cells, 1 × 10⁶ live unlabeled cells, and 8 × 10⁵ dead unlabeled cells (▲);1 × 10⁶ [125]IUdR-labeled cells and 1 × 10⁶ live unlabeled cells (▽); and 1 × 10⁶ [125]IUdR-labeled cells and 1 × 10⁶ dead unlabeled cells (◆). Tumor volumes were assessed, and the data were plotted as mean ± SEM (*n* = 10 per group). At each time point, the differences between the mean tumor volumes for each experimental group and those for the controls were determined by using the Student's *t* test. NS, not significant; *, *P* < 0.05; **, *P* < 0.01.

cell) are cytocidal. Because the DNA-incorporated [125]IUdR within such cells may be released after their death and degeneration and could, therefore, be taken up by adjoining DNA-synthesizing tumor cells, the retention of radioactivity was measured in the legs of mice injected s.c. with 0.25 × 10⁶ dead (frozen and thawed three times) [125]IUdR-labeled tumor cells premixed with an equal number of LS174T cells. The data indicate that 98% of the radioactivity released by the killed [125]IUdR-labeled cells was eliminated from the s.c. tumors within 24 hours of their injection. After this initial rapid washout of radioactivity, the decrease in radioactivity was slowed and reached background levels by day 14. These results show minimal reutilization by the coinjected tumor cells of the radioactivity released by killed [125]IUdR-labeled cells. The findings agree with those reported for a different tumor-cell line (20).

Radiation Dose Calculations. The decay of ^{125}I produces both low-energy electrons and low-energy gamma radiation. With ≈90% and 99% of the emitted electrons having, respectively, a range of <50 nanometers and <0.5 micrometers (13, 14), most of the electrons emitted from [125]IUdR-labeled cells cannot cause direct damage to neighboring or distant cells (15, 16). However, because (*i*) some of the electrons emitted have ranges that are greater than a mammalian cell diameter, and (*ii*) the 35.5 keV photons emitted during the decay of ^{125}I have a mean free path for energy absorption in soft tissue of 5–10 cm (21), the [125]IUdR-labeled cells will deposit a small


Fig. 2. Relationship of LS174T tumor-associated radioactivity and tumor size in bystander study. Two groups of nude mice were injected s.c. with 1 × 10⁶ [125]IUdR-labeled cells + 1 × 10⁶ live cells (□) or 2 × 10⁵ [125]IUdR-labeled cells + 1 × 10⁶ live cells + 8 × 10⁵ dead cells (■). Tumor radioactivity and tumor volume were determined 15 days after the injection, and the data were plotted as mean ± SEM (*n* = 5 per group). Left bars represent radioactivity; right bars are tumor volumes (as percentage of control mice injected with 1 × 10⁶ live cells + 1 × 10⁶ dead cells).

dose that might damage unlabeled neighboring or distant cells by cross fire. To determine the absorbed dose from these radiations and to estimate possible radiobiologic effects, we adopted the approaches recommended for calculating radiation dose from homogeneously distributed radioactivity (22). The retention of radioactivity was measured in the legs of mice injected s.c. with 5 × 10⁵ [125]IUdR-labeled cells premixed with an equal number of LS174T cells. An apparent two-phase washout of radioactivity was observed: an initial rapid component that reached ≈35% by day 1 and a slower component that reached 10% by day 6 (Fig. 3). We used these data, tumor growth kinetics, cell size, and the medical internal radiation dose (MIRD) S values for iodine-125 (23) to calculate the absorbed dose (see supporting information for details). The calculations indicate that under the experimental conditions that lead to statistically significant retardation/inhibition of tumor growth (Fig. 1), ≈1–7 cGy were deposited in the growing tumors (day 0 to day 15) when varying numbers of [125]IUdR-labeled cells were premixed with unlabeled LS174T cells.

***In Vivo* Growth of γ-Irradiated Tumor Cells and Substantiation of the ^{125}I-Based Bystander Effect.** To evaluate the effects of radiation dose on the growth of LS174T tumor cells *in vivo*, groups of nude mice were injected s.c. with tumor-cell suspensions composed of 1 × 10⁶ cells that had just been exposed to external γ-radiation doses of 0, 50, 100, or 200 cGy and an equal number of dead tumor cells. The growth of these tumor cells was monitored up to 14 days. With the exception of the cells irradiated with 200 cGy, there were no differences in the rate of tumor growth among the other study groups.

Based on this evidence and our dosimetric estimates indicating

Fig. 3. Retention by s.c. LS174T tumor of radioactivity from the inoculation of ^{125}IUdR-labeled tumor cells. Nude mice were injected s.c. with 5×10^5 ^{125}IUdR-labeled cells mixed with an equal number of live tumor cells. The total radioactivity in the tumors was measured at various time points after injection. Dashed line represents linear fit of data points (●).

that <7 cGy was deposited by the ^{125}IUdR-labeled cells in the unlabeled cells within the growing s.c. tumors (Fig. 1), the contribution of direct γ-radiation dose to the *in vivo* inhibition of tumor growth can be ruled out. We conclude, therefore, that the inhibitory effect of ^{125}IUdR-labeled cells on *in vivo* growth of unlabeled tumor cells is clearly a consequence of a bystander effect.

Effect of γ-Irradiated "Dying" Tumor Cells on Growth of Unirradiated Cells. The demonstration of an inhibitory bystander effect on tumor growth with ^{125}IUdR-labeled cells led us to ask whether a similar effect could be shown with dying γ-irradiated tumor cells. Tumor cells exposed to either 5 or 20 Gy of γ radiation (1×10^6 cells) were mixed immediately with live LS174T tumor cells (1×10^6 cells). The cells were then injected s.c. into groups of nude mice. The *in vivo* tumor sizes were compared, and no bystander effect from the γ-irradiated tumor cells on the *in vivo* tumor growth of unirradiated tumor cells was observed.

Discussion

It has long been accepted that radiation-induced biologic effects, such as decreased cell survival, increased levels of sister chromatid exchanges, mutations, and micronuclei formation, changes in gene expression, and oncogenic transformation, occur only as a consequence of direct/indirect ionization and damage to the intranuclear DNA of mammalian cells. However, recent *in vitro* studies have provided strong evidence that unirradiated cells react to signals produced by irradiated cells (1–11), and there is now data indicating that this phenomenon also occurs when *ex vivo* irradiated cells are administered to animals (12). If a bystander effect were to occur after the irradiation of cells within an animal, it would greatly impact current (*i*) interpretations of the mechanisms underlying cell death after external beam and radionuclide therapy, (*ii*) assessment of therapeutic response to radionuclide therapy, and (*iii*) risk

estimations after the administration of diagnostic radiopharmaceuticals to patients or the inadvertent exposure of individuals or populations to radioactivity.

To determine whether the bystander effect could be a consequence of *in vivo* irradiation, we selected a radionuclide (^{125}I) with unique decay characteristics and a well established animal tumor model (human LS174T adenocarcinoma cells that grow as s.c. tumors in nude mice as approximately spherical tumors). The experimental approach we have used is simple. LS174T cells are labeled *in vitro* with ^{125}I at a DNA-incorporated radioactive concentration that is lethal to the labeled cells but that deposits minimal energy in neighboring cells, i.e., there is insignificant cross fire. The radiolabeled cells are then mixed with unlabeled tumor cells, injected s.c. into mice, and the size of the consequent tumors is determined over time. Under such conditions, any alteration in the growth of the tumor will be a consequence of an *in vivo*, radiation-initiated bystander effect.

The Auger electron emitter iodine-125 is an isotope with physical decay characteristics that are ideal for the intended studies. Auger electron emission from certain radioactive atoms occurs whenever an inner shell vacancy is created. These primary vacancies can be induced by electron capture or internal conversion. The highly excited residual atom de-excites with the emission of several to many low-energy (<1 keV) electrons (Auger, Coster–Kronig, and super Coster–Kronig transitions) or atomic shell X-rays. Monte Carlo calculations, performed to determine the electron spectra of such radionuclides (13, 14), have shown them to be extremely complex and to consist primarily of electrons having subcellular ranges (nanometers). For ^{125}I, the average Auger and Coster–Kronig electron spectra give a total of about 20 electrons per decay with energies ranging from ≈15 to 24 keV. The ejection of these electrons leaves the decaying atoms transiently with a high positive charge and results in the deposition of a concentrated amount of energy (1×10^6 to 1×10^9 cGy per decay) in an extremely small volume around the decay site, typically on the order of a few cubic nanometers (15). The highly localized nature of energy absorption leads to severe damage of molecular structures only in the immediate vicinity of the decaying atom (19, 24). *In vitro* studies at the molecular and cellular levels have repeatedly demonstrated (*i*) the very high toxicity and efficient double-strand break formation when such radionuclides decay in close proximity to nuclear DNA (15, 17–19, 25, 26), and (*ii*) the relative ineffectiveness of these radionuclides when the decay occurs in the cytoplasm or outside the cell (16, 27).

The LS174T cells were radiolabeled with ^{125}I by incubating logarithmically growing cells with the thymidine analog ^{125}IUdR. These cells were then mixed with unlabeled cells and injected s.c. into mice. The unique properties of ^{125}IUdR offer significant advantages for the exploration of the bystander effect *in vivo*. First, after its phosphorylation and DNA incorporation, the radioactive atom has been found to be indefinitely bound to DNA for the life of the cell and/or its progeny (15, 28, 29). When we followed the time course of radioactivity in s.c. tumors (Fig. 3), we also did not detect evidence of reutilization. As a control, we coinjected labeled cells that had been killed (three freeze–thaw cycles) before injection and observed that 98% of the radioactivity disappears within 24 h. Consequently, we conclude that reutilization of ^{125}I does not account for/contribute to the decreased tumor growth observed. Second, as the ^{125}IUdR-labeled cells are destined to die, the factor(s) responsible for the observed bystander effect should be present only during the first few days after tumor-cell injection. Third, even though ^{125}I also emits low-energy γ photons that travel multicellular distances, potentially damaging cells by cross fire, our dose estimates (see supporting information for details of dose calculation) indicate that <7 cGy are deposited in the s.c. tumors during their growth (days 0–15), whereas γ irradiation of these tumor cells with up

to 100 cGy, i.e., more than 10 times the calculated γ-radiation dose from ^{125}IUdR-labeled cells, has no detectable effect on their growth *in vivo*. The distinct differences between the lethal doses to the labeled cells and the insignificant nonlethal doses to the unlabeled cells lead us to conclude that the growth inhibitory or toxic effect of ^{125}IUdR-labeled cells on the neighboring or distant unlabeled tumor cells is a consequence of an *in vivo* induced bystander effect, presumably initiated by the irradiation of the labeled cell DNA by Auger electrons.

The tumor in our experiments is assumed to be made of a closely packed collection of cells. In such a configuration, each tumor cell will be in contact with a number of neighboring cells. Therefore, if physical contact between each of the ^{125}IUdR-labeled and unlabeled cells is necessary for the observed bystander effect to manifest itself, as has been reported in several *in vitro* studies (4, 7), one would expect a substantial decrease in tumor growth retardation/inhibition when the ratio of the radiolabeled-to-unlabeled cells approaches a value that no longer assures each unlabeled cell to be in contact with a labeled cell. We observed similar growth retardation/inhibition whether the ^{125}IUdR-labeled-to-unlabeled cell ratio is 1:1 or 1:5 ($P < 0.05$ when these tumor volumes are compared with those of the controls). When this ratio drops to 1:10 (Fig. 1), the effectiveness of the radiolabeled cells declines but the differences among the three experimental groups are statistically insignificant ($P > 0.05$). It thus appears that once the ratio of the radiolabeled cells to unlabeled cells rises above the minimum needed to cause the bystander effect, the same retardation/inhibition in tumor growth occurs, suggesting that *in vivo* the bystander effect is a binary "all or none" phenomenon. This conclusion is in agreement with the hypothesis recently expressed by Brenner and coworkers (6).

The mechanisms underlying the radiation-induced bystander effect are poorly understood. Many investigators have reported an increased expression of p53 in irradiated cells (30, 31), as well as of the Cdk inhibitor p21$^{CIP1/WAF1}$ (32), CD95 (APO-1/Fas), death receptors and ligands (33, 34), cytokines (35, 36), reactive oxygen species (37), caspase-8 (38), and nitric oxide (39). Increased expression of p53 and p21^{WAF1} in unirradiated bystander cells cocultured with α-particle-irradiated cells has also been reported (4). Other workers have implicated the release of a factor into the culture medium from γ-irradiated cells as playing a role in the induction of an *in vitro* bystander effect (11). Additionally, investigators have presented evidence for the involvement of gap-junction-mediated intercellular communication in *in vitro* bystander effect studies (4, 8). These findings suggest that a damage signal or signals from irradiated cells is probably transferred to the unirradiated bystander cells through a range of signaling pathways. If similar pathways underlie the *in vivo* bystander effects of ^{125}I decay described in this paper, new therapeutic regimens for cancer may be devised by combining both radionuclide-based therapy and biologic modification of, or

intervention in, various steps of signaling pathways to achieve greater effectiveness. There is a good likelihood that the bystander effect observed (Fig. 1) is a direct consequence of signal(s) initiated by ^{125}I decays occurring *in vivo* because, when the radiolabeled cells were killed by three freeze–thaw cycles before mixing with an equal number of unlabeled cells, only a very small and statistically insignificant decrease in tumor growth was observed. Finally, whether the bystander effect is restricted *in vivo* to the highly specific damage to DNA by ionization secondary to Auger electron cascades is yet to be determined.

The bystander effect induced *in vivo* by radioactive decay also introduces a concept that dramatically impacts our views on risk assessment after the administration of radiopharmaceuticals to patients or the inadvertent exposure of individuals/populations to radioactivity. Traditionally (22), dose estimations have been carried out by averaging the radiation dose to cells within a tissue/organ/tumor mass from radioactive atoms present on/within the cells (self dose) and that from radionuclides present in or on other cells or in the extracellular fluids (cross dose). Such absorbed dose estimates, based on the decay characteristics of the radionuclide in question, have played an important role in determining the amount of radioactivity to be administered to patients in diagnostic/therapeutic procedures as well as in assessing environmental radiation risks, for example, radon inhalation. When a bystander effect is factored in, the actual radiobiologic response should be greater than that predicted by dosimetric estimates alone.

The decay of an Auger-electron-emitting radionuclide in close proximity to nuclear DNA is highly toxic to mammalian cells *in vitro* (15, 17–19, 40, 41). Consequently, investigators have assessed the therapeutic potential of such radionuclides and have shown them to be efficacious in animals bearing ovarian tumors (42, 43), brain tumors (44), s.c. tumors (45), and, recently, spinal cord tumors (46). Despite these positive findings, some investigators have refrained from pursuing the therapeutic potential of Auger-electron-emitting radionuclides, because the short ranges of the emitted electrons ($\approx$99% have a range <0.5 μm) would seem to require the presence of the radionuclide within each and every targeted tumor cell. They have, rather, focused their efforts on using medium- to high-energy, electron-emitting isotopes that permit cross fire. Our current findings, in which the presence of ^{125}I-containing cells within a growing tumor mass leads to substantial and statistically significant retardation in the growth of a tumor (Fig. 1), demonstrate that the biologic effects are not limited to radiolabeled cells only but also extend to neighboring cells. The presence of this bystander effect should encourage investigators to use Auger-electron-emitting radionuclides for therapy.

1. Nagasawa, H. & Little, J. B. (1992) *Cancer Res.* **52,** 6394–6396.
2. Hickman, A. W., Jaramillo, R. J., Lechner, J. F. & Johnson, N. F. (1994) *Cancer Res.* **54,** 5797–5800.
3. Nagasawa, H. & Little, J. B. (1999) *Radiat. Res.* **152,** 552–557.
4. Azzam, E. I., de Toledo, S. M. & Little, J. B. (2001) *Proc. Natl. Acad. Sci. USA* **98,** 473–478.
5. Sawant, S. G., Randers-Pehrson, G., Geard, C. R., Brenner, D. J. & Hall, E. J. (2001) *Radiat. Res.* **155,** 397–401.
6. Brenner, D. J., Little, J. B. & Sachs, R. K. (2001) *Radiat. Res.* **155,** 402–408.
7. Bishayee, A., Rao, D. V. & Howell, R. W. (1999) *Radiat. Res.* **152,** 88–97.
8. Bishayee, A., Hall, H. Z., Stein, D., Rao, D. V. & Howell, R. W. (2001) *Radiat. Res.* **155,** 335–344.
9. Howell, R. W. & Bishayee, A. (2002) *Micron* **33,** 127–132.
10. Mothersill, C. & Seymour, C. (1997) *Int. J. Radiat. Biol.* **71,** 421–427.
11. Mothersill, C. & Seymour, C. B. (1998) *Radiat. Res.* **149,** 256–262.
12. Watson, G. E., Lorimore, S. A., Macdonald, D. A. & Wright, E. G. (2000) *Cancer Res.* **60,** 5608–5611.
13. Charlton, D. E. & Booz, J. (1981) *Radiat. Res.* **87,** 10–23.
14. Sastry, K. S. R. & Rao, D. V. (1984) in *Physics of Nuclear Medicine: Recent Advances*, eds. Rao, D. V., Chandra, R. & Graham, M. C. (Am. Inst. Phys., Woodbury, NY), pp. 169–208.
15. Kassis, A. I., Sastry, K. S. R. & Adelstein, S. J. (1987) *Radiat. Res.* **109,** 78–89.
16. Kassis, A. I., Fayad, F., Kinsey, B. M., Sastry, K. S. R., Taube, R. A. & Adelstein, S. J. (1987) *Radiat. Res.* **111,** 305–318.
17. Hofer, K. G. & Hughes, W. L. (1971) *Radiat. Res.* **47,** 94–109.
18. Porteous, D. D. (1971) *Br. J. Cancer* **25,** 594–597.
19. Chan, P. C., Lisco, E., Lisco, H. & Adelstein, S. J. (1976) *Radiat. Res.* **67,** 332–343.
20. Dethlefsen, L. A. (1970) *J. Natl. Cancer Inst.* **44,** 827–840.
21. Storm, E. & Israel, H. I. (1970) *Nucl. Data Tables* **A8,** 1–198.

22. Loevinger, R., Budinger, T. F. & Watson, E. E. (1991) *MIRD Primer for Absorbed Dose Calculations, Revised* (Soc. Nucl. Med., New York).
23. Goddu, S. M., Howell, R. W. & Rao, D. V. (1994) *J. Nucl. Med.* **35,** 303–316.
24. Deutzmann, R. & Stöcklin, G. (1981) *Radiat. Res.* **87,** 24–36.
25. Walicka, M. A., Adelstein, S. J. & Kassis, A. I. (1998) *Radiat. Res.* **149,** 134–141.
26. Kassis, A. I., Walicka, M. A. & Adelstein, S. J. (2000) *Acta Oncol.* **39,** 721–726.
27. Hofer, K. G., Harris, C. R. & Smith, J. M. (1975) *Int. J. Radiat. Biol.* **28,** 225–241.
28. Hofer, K. G., Prensky, W. & Hughes, W. L. (1969) *J. Natl. Cancer Inst.* **43,** 763–773.
29. Dethlefsen, L. A. (1969) *Cancer Res.* **29,** 1717–1720.
30. Lowe, S. W., Schmitt, E. M., Smith, S. W., Osborne, B. A. & Jacks, T. (1993) *Nature* **362,** 847–849.
31. Lu, X. & Lane, D. P. (1993) *Cell* **75,** 765–778.
32. Dulic, V., Kaufmann, W. K., Wilson, S. J., Tisty, T. D., Lees, E., Harper, J. W., Elledge, S. J. & Reed, S. I. (1994) *Cell* **76,** 1013–1023.
33. Albanese, J. & Dainiak, N. (2000) *Radiat. Res.* **153,** 49–61.
34. Gong, B. & Almasan, A. (2000) *Cancer Res.* **60,** 5754–5760.
35. Narayanan, P. K., LaRue, K. E. A., Goodwin, E. H. & Lehnert, B. E. (1999) *Radiat. Res.* **152,** 57–63.
36. Epperly, M. W., Gretton, J. A., DeFilippi, S. J., Sikora, C. A., Liggitt, D., Koe, G. & Greenberger, J. S. (2001) *Radiat. Res.* **155,** 2–14.
37. Hachiya, M., Osawa, Y. & Akashi, M. (2000) *Biochim. Biophys. Acta* **1495,** 237–249.
38. Belka, C., Heinrich, V., Marini, P., Faltin, H., Schulze-Osthoff, K., Bamberg, M. & Budach, W. (1999) *Int. J. Radiat. Biol.* **75,** 1257–1264.
39. Matsumoto, H., Hayashi, S., Hatashita, M., Ohnishi, K., Shioura, H., Ohtsubo, T., Kitai, R., Ohnishi, T. & Kano, E. (2001) *Radiat. Res.* **155,** 387–396.
40. Kassis, A. I., Adelstein, S. J., Haydock, C., Sastry, K. S. R., McElvany, K. D. & Welch, M. J. (1982) *Radiat. Res.* **90,** 362–373.
41. Makrigiorgos, G. M., Kassis, A. I., Baranowska-Kortylewicz, J., McElvany, K. D., Welch, M. J., Sastry, K. S. R. & Adelstein, S. J. (1989) *Radiat. Res.* **118,** 532–544.
42. Bloomer, W. D. & Adelstein, S. J. (1977) *Nature* **265,** 620–621.
43. Baranowska-Kortylewicz, J., Makrigiorgos, G. M., Van den Abbeele, A. D., Berman, R. M., Adelstein, S. J. & Kassis, A. I. (1991) *Int. J. Radiat. Oncol. Biol. Phys.* **21,** 1541–1551.
44. Kassis, A. I., Wen, P. Y., Van den Abbeele, A. D., Baranowska-Kortylewicz, J., Makrigiorgos, G. M., Metz, K. R., Matalka, K. Z., Cook, C. U., Sahu, S. K., Black, P. M., *et al.* (1998) *J. Nucl. Med.* **39,** 1148–1154.
45. Behr, T. M., Sgouros, G., Vougioukas, V., Memtsoudis, S., Gratz, S., Schmidberger, H., Blumenthal, R. D., Goldenberg, D. M. & Becker, W. (1998) *Int. J. Cancer* **76,** 738–748.
46. Kassis, A. I., Dahman, B. A. & Adelstein, S. J. (2000) *Acta Oncol.* **39,** 731–737.